Image

The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation

The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic and can lead to valve regurgitation and a poor prognosis. At present, atrial fibrillation ablation is one of the most effective means for the recurrence of atrial fibrillation in clinical practice, but the recurrence rate is high. Therefore, it is of great significance to find the predictors of relapse after atrial fibrillation ablation for clinical precision treatment. three-dimensional transesophageal ultrasound (3D-TEE) can comprehensively evaluate the valve regurgitation, flap ring changes, atrial or auricular thrombosis in patients with atrial fibrillation. It is also a necessary examination before atrial fibrillation ablation.

Therefore, this study intends to combine 3D-TEE and three-dimensional transthoracic echocardiographic (3D-TTE) examination to evaluate the cardiac structure and function of patients. To comprehensively evaluate atrial fibrillation valve regurgitation and explore the predictors of recurrence after atrial fibrillation ablation.

Description

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. It is characterized by disturbance of atrial electromechanical activity, and the incidence rate of the general population can reach 1.5-2%. Valvular regurgitation may be associated with atrial fibrillation, leading to poor prognosis. However, due to limited screening techniques, it is difficult to comprehensively evaluate valvular regurgitation and its influencing factors. On the other hand, AF may lead to reduced heart function, atrial or auricular thrombosis, and lead to high risk events such as ischemic stroke and heart failure.

Therefore, restoring normal sinus rhythm is of great significance for patients with atrial fibrillation. Atrial fibrillation ablation is one of the most effective methods for atrial fibrillation reversion, which is of great significance for improving the prognosis of patients. However, although the current ablation is very mature and effective, the recurrence rate one year after the first ablation can reach 20 to 40%. The high recurrence rate not only increases the readmission risk of patients and increases the economic burden, but also makes some patients shy away from ablation therapy and delay treatment, resulting in adverse outcomes. At present, there is a lack of effective indicators for predicting the recurrence of atrial fibrillation after ablation in clinical practice. Therefore, it is of great significance to search for predictive factors for the recurrence of atrial fibrillation after ablation in clinical precision treatment.

three-dimensional transesophageal ultrasound (3D-TEE) can comprehensively evaluate the valve regurgitation, flap ring changes, atrial or auricular thrombosis in patients with atrial fibrillation. It is also a necessary examination before atrial fibrillation ablation.

Therefore, this study intends to combine 3D-TEE and three-dimensional transthoracic echocardiographic (3D-TTE) examination to evaluate the cardiac structure and function of patients. To comprehensively evaluate atrial fibrillation valve regurgitation and explore the predictors of recurrence after atrial fibrillation ablation.

Eligibility

Inclusion Criteria:

  1. Age ≥18 years old;
  2. Patients who came to the hospital with atrial fibrillation and intended to undergo ablation.

Exclusion Criteria:

  1. - History of left atrial or left atrial appendix thrombus, new cerebral infarction and myocardial infarction (< 6 months);
  2. Congenital heart disease, valvular heart disease, dilated heart disease, hypertrophic cardiomyopathy, pacemaker implantation, artificial valve replacement;
  3. hyperthyroidism, severe liver and kidney insufficiency;
  4. Proposed cardiac pacemaker implantation;
  5. Previous history of catheter ablation;
  6. The quality of three-dimensional transesophageal images was insufficient and could not be analyzed;
  7. refuse to sign the informed consent.

Study details
    Atrial Fibrillation (AF)
    Mitral Regurgitation
    Tricuspid Regurgitation

NCT07085650

First Hospital of China Medical University

16 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.